|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
US9789182B2
(en)
|
2012-10-23 |
2017-10-17 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
|
|
WO2014071419A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
AU2014323523B2
(en)
|
2013-09-20 |
2020-02-20 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
MX374633B
(es)
*
|
2014-08-01 |
2025-03-06 |
Solventum Intellectual Properties Company |
Combinaciones terapeuticas para usarse en el tratamiento de tumores.
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
US10688171B2
(en)
|
2015-02-10 |
2020-06-23 |
Ohio State Innovation Foundation |
Chlamydia-activated B cell platforms and methods thereof
|
|
EP3268037B1
(en)
*
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
JP2018508593A
(ja)
|
2015-03-20 |
2018-03-29 |
シンダックス ファーマシューティカルズ，インコーポレイティド |
がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
EP3839510A3
(en)
*
|
2015-04-17 |
2021-08-25 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
KR20200091499A
(ko)
|
2015-05-06 |
2020-07-30 |
스니프르 테크놀로지스 리미티드 |
미생물 개체군 변경 및 미생물군 변형
|
|
EP3892284B1
(en)
|
2015-05-29 |
2024-05-22 |
Merck Sharp & Dohme LLC |
Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
|
|
CA2986765A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
EP3744340A3
(en)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
EP3349731B1
(en)
|
2015-09-16 |
2023-11-01 |
Board of Regents, The University of Texas System |
Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
|
|
US11639389B2
(en)
*
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
US11466253B2
(en)
|
2015-10-22 |
2022-10-11 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
TWI805542B
(zh)
*
|
2015-10-23 |
2023-06-21 |
日商坎巴斯有限公司 |
用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合
|
|
EP3364995B1
(en)
*
|
2015-10-23 |
2021-08-04 |
Apogenix AG |
Single-chain cd27-receptor agonist proteins
|
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
ES2894691T3
(es)
*
|
2015-11-04 |
2022-02-15 |
Astellas Pharma Inc |
Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo
|
|
AU2016349632A1
(en)
|
2015-11-07 |
2018-05-24 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP7086000B2
(ja)
|
2015-11-10 |
2022-06-17 |
オハイオ・ステート・イノヴェーション・ファウンデーション |
体液性親和性の加速に関する方法及び組成物
|
|
KR102883915B1
(ko)
|
2015-12-16 |
2025-11-18 |
시애틀 프로젝트 코포레이션 |
신생항원 동정, 제조, 및 용도
|
|
JP7000322B2
(ja)
|
2015-12-16 |
2022-02-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗ｌａｇ３抗体および抗原結合性フラグメント
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
US20210000921A1
(en)
*
|
2016-01-11 |
2021-01-07 |
Flagship Pioneering Innovations V. Inc. |
Methods and compositions for modulating thymic function
|
|
US10993985B2
(en)
|
2016-02-23 |
2021-05-04 |
BioLmeRx Ltd. |
Methods of treating acute myeloid leukemia
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
MX389710B
(es)
|
2016-05-27 |
2025-03-20 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
CN109563481B
(zh)
|
2016-07-13 |
2024-01-05 |
俄亥俄州创新基金会 |
用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
CN116196425A
(zh)
|
2016-09-27 |
2023-06-02 |
得克萨斯系统大学评议会 |
通过调节微生物组来增强免疫检查点阻断疗法的方法
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
CA3040458A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
WO2018089423A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
MA46852A
(fr)
|
2016-11-17 |
2019-09-25 |
Univ Texas |
Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
|
|
AU2017372856B9
(en)
|
2016-12-05 |
2024-01-04 |
Pharmacosmos Holding A/S |
Preservation of immune response during chemotherapy regimens
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
CN110381997A
(zh)
|
2016-12-12 |
2019-10-25 |
茂体外尔公司 |
用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
|
|
EP3586136B1
(en)
|
2017-02-24 |
2023-11-08 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
EP3624848A1
(en)
|
2017-05-19 |
2020-03-25 |
Syndax Pharmaceuticals, Inc. |
Combination therapies
|
|
CA3060984A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
KR102721137B1
(ko)
|
2017-05-30 |
2024-10-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
|
|
EP3647433B1
(en)
|
2017-06-30 |
2023-04-12 |
Osaka University |
Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index
|
|
TWI817952B
(zh)
|
2017-08-25 |
2023-10-11 |
美商戊瑞治療有限公司 |
Ｂ７－ｈ４抗體及其使用方法
|
|
WO2019075112A1
(en)
|
2017-10-10 |
2019-04-18 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
KR20260008173A
(ko)
|
2017-11-22 |
2026-01-15 |
시애틀 프로젝트 코포레이션 |
신생항원에 대한 접합 에피토프 제시 감소
|
|
WO2019113072A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Intendet Services, Inc. |
Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
|
|
WO2019118826A1
(en)
|
2017-12-15 |
2019-06-20 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer using exosomes-associated gene editing
|
|
BR112020016986A2
(pt)
|
2018-02-21 |
2021-03-02 |
Five Prime Therapeutics, Inc. |
formulações de anticorpo contra b7-h4
|
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
SG11202009504YA
(en)
|
2018-03-25 |
2020-10-29 |
Snipr Biome Aps |
Treating & preventing microbial infections
|
|
CA3094108A1
(en)
|
2018-03-27 |
2019-10-03 |
Board Of Regents, The University Of Texas Systems |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
|
AU2019242912B2
(en)
|
2018-03-28 |
2025-07-17 |
Board Of Regents, The University Of Texas System |
Identification of epigenetic alterations in DNA isolated from exosomes
|
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
MA52889A
(fr)
|
2018-06-15 |
2021-04-21 |
Flagship Pioneering Innovations V Inc |
Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
|
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
CA3120709A1
(en)
|
2018-11-21 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020112493A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
WO2020136879A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立大学法人大阪大学 |
悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤
|
|
EP3918332B1
(en)
*
|
2019-01-30 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
US12492380B2
(en)
|
2019-05-09 |
2025-12-09 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
WO2020236562A1
(en)
|
2019-05-17 |
2020-11-26 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
US20220396839A1
(en)
|
2019-11-12 |
2022-12-15 |
Foundation Medicine, Inc. |
Methods of detecting a fusion gene encoding a neoantigen
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
US12251449B2
(en)
|
2019-12-19 |
2025-03-18 |
William Marsh Rice University |
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
|
|
CA3161733A1
(en)
|
2020-01-07 |
2021-05-15 |
Everett Stone |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
WO2021155113A1
(en)
|
2020-01-29 |
2021-08-05 |
Board Of Regents, The University Of Texas System |
Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
|
|
US20230069749A1
(en)
|
2020-01-29 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Use of poziotinib for the treatment of cancers with nrg1 fusions
|
|
US20230106973A1
(en)
|
2020-02-17 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
WO2021177822A1
(en)
*
|
2020-03-06 |
2021-09-10 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Modulating anti-tumor immunity
|
|
TW202208418A
(zh)
|
2020-05-21 |
2022-03-01 |
美國德州系統大學評議委員會 |
具有vgll1特異性之t細胞受體及其用途
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
EP4243839A1
(en)
|
2020-11-13 |
2023-09-20 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
AU2021388155A1
(en)
|
2020-11-25 |
2023-06-15 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
CA3205538A1
(en)
|
2021-01-19 |
2022-07-28 |
Han XIAO |
Bone-specific delivery of polypeptides
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4359570A4
(en)
|
2021-06-25 |
2025-04-30 |
Foundation Medicine, Inc. |
METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
US20250114452A1
(en)
|
2021-08-04 |
2025-04-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
MX2024004122A
(es)
|
2021-10-05 |
2024-05-13 |
Cytovia Therapeutics Llc |
Células citolíticas (asesinas) naturales y métodos de uso de las mismas.
|
|
PE20242001A1
(es)
|
2021-10-20 |
2024-09-27 |
Takeda Pharmaceuticals Co |
Composiciones que actuan sobre bcma y metodos de uso de estas
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
CA3253038A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|